Thank you, David.
candidates. our clearance the significant for LP-XXX a activated trial application received basket you many Phase June, FDA I’ve in milestone As our our IND already know, sites clearance drug IND our our we the novel leveraging advance and of for The for trial. of application AI machine to X for initial pipeline clinical LP-XXX and validating program, of learning approach for was
our to action, from stratification ideal literally development within generating and XX we has and RADR months. prioritizing process aided selection. blockbuster of signatures pursue weeks instrumental in subtypes trials signatures which cancer with no that clinical biomarker limited of platform that us AI its and identifying or therapeutic multiple help would’ve of Insights of LP-XXX were We to the and discovering patients use We to a months, or these in normally tumors mechanism have year future and in can CNS patient that taken effective developed sometimes for LP-XXX potential a half many solid with advanced options. cancers, believe our types
$X $X aggregate estimated a today billion and to We’re than cancers, both drug opportunity CNS to of Globally, metastasis. the excited about tumors billion as for for over billion and three ago. in another market even LP-XXX this be $XX more billion years result about and consisting is the for arising primary two those solid of $X annual potential
LP-XXX is meet there’s use patients no entirely drug molecule has uncover escalating been and platform to the design. trial, underserved and needs areas safety and candidates the a highly in believe XX basket to human with first buoyant of internally to our using in and the or we of first therapeutic options. a our of AI developed tolerability we designed subtypes, to trial can the where be where now X Phase assess is will This doses advanced significant evaluate
additional DNA target cancers believe of and damage later exceptional we be for trial. an the also that seen that’ll phases that also results We deficiencies, response have have in
screening completing The trial We sites we for anticipate been dosing in patients with have sometime opened actively initial XXXX. are trial LP-XXX. and the
comparative whiteboard drug The exciting in derived RADR million. under cost human new the with Another estimated our X.X from a very even went from molecule. developed very AI platform. in that promising molecule This trial public. first pipeline under of on years, data insights we initial large of our mechanism not is It’s clinical to one an around specific a we scale was and would lethality synthetic using $X
year. We then LP-XXX and lymphoma. fourth to studies an ramp in preparing up and mechanisms. orphan Today, which quarter these LP-XXX led its the while of clinical human designation cell for a we X are continuing to leveraged to indications our GMP process develop Phase in expect mantle trial, the for launch we molecule refine sister first Ultimately, efficiently to this manufacturing also
X complete, the cell I earlier, we lymphoma. and to have lymphomas, we of cell anticipate double the billion very we subtypes times also with the mentioned designation As the are is we drug submitting number FDA $X.X IND these received and is that now the studies think about this for that mantle non-Hodgkin’s The mantle IND-enabling aggressive currently end by and in hit this market globally in believe orphan month, X.X U.S. and about to lymphomas Europe, number. already
wide agents. as levels tumors monotherapy range preference selected expression in also deficiencies potency with combination and a other in in LP-XXX LP-XXX has represent DNA cancers, solid for synthetic has repair of high and franchise, which that PTGRX our have significant lethality shown or LP-XXX of pathways. the both
has hematologic or lymphoma shown they LP-XXX lymphomas, a namely range to of potent While and ability become Ibrutinib malignancies, mantle also to shows Bortezomib. regress have after cell in both wide seen effectively efficacy refractory that xenografts we LP-XXX non-Hodgkin’s
will a from tumors, cancer focusing in trials early will centers those Phase Texas have been as range the activity pursued once and LP-XXX believe promising LP-XXX which such with Health and and into research trials. be Children’s, shown we Greehey also have established children’s X be of candidates drug Both safety of and University pediatric dosing that on
significant of and including has a a sarcomas, demonstrated cancers impact sarcoma both range Ewing on LP-XXX wide We also rhabdomyosarcoma, largely. know pediatric that
the these has the modeling indications Cancer a and at teratoid published Additionally, the studies of LP-XXX reporting toward largely namely tumor, was Institute under age designation approved pretty chromatin rhabdoid plan mechanism unique from emerging drug atypical we five. and granted deficient of with these pointing potential children and rare looking tumors, disease which SMARCBX, details reflects this We ultra pediatric ATRT, publication year. in more standard care we later out cancer, National rare and where agents uncovered of the this no on
moving smokers Harmonic patients LP-XXX, our X Now, of sites trial we for our additional clinical lung initial and five have in non-small to have on never added. cancer trial that LP-XXX X Phase Phase we of trial cell and dosed, been active
sites multiple additional add trial also expect patients. quarter and We to this throughout
increasingly direct and increased briefings. also investigator awareness we’re and groups, greater the increasing we’re a among screening. as screening number also of interactions comes We’re patient This of result – advocacy patients
Cancer Dr. a Dr. lead cancer Chase principal Joseph stellar for recently smoker patient Treat Phase appointed irrespective X focused Center brings Fox investigator Additionally, clinical as the trials community, background study. their Treat never never background status. the not and driver the focus only smoked, also in of had but Harmonic X in but leading plus lung was has been of Stage serving of interventional never disease population. on He who with mutation smokers trial a them XXX
ideal with and active network we his in an and also trial, experience and backdrop the the welcome it’s So clinical Harmonic and Lantern. Harmonic leadership for
and XX and key of to the care survival of incidence progression-free Asia, survival. lung is LP-XXX cancer that patients XX X potential being never between a in smokers The open-label should the also overall with we with randomized is trial combination trial, chemotherapy investigate countries have exploring with We’re standard this months. to trial Harmonic Overall, patients. of XX Phase targeting higher which two last specifically anticipate endpoints designed measured into enrollment arm the expand
never increase overall never in XX% saw year population chemotherapy that – the overall were lung LP-XXX we LP-XXX what group cancer was with smoker two survival, received a with smokers same trial, clinical of significant in and chemo the X Phase never subset multicenter of that the of of cell standard care increase that showed given in increase previous in non-small XXX% of a smokers chemo progression-free survival survival In of a that versus doublet.
with We potency our to to concentrations. to ADCs I discussed platform. focus of and synthesize develop the University, to next AI anti-tumor Bielefeld linked of an drug fairly several This ADCs also novel collaboration collaboration stride development interest conjugates. antibody in promising of of The molecule, the exciting earlier, exciting initial using molecules our signifies generation to evaluate of forward antibody attach partnership is RADR This a these using of linker is the picomolar we the ADCs to class strategy. their unique ultra-low can cryptophycins. due a breakthrough believe
lines, the The cell vitro will and coming testing we vivo undergo rigorous ADCs cryptophycin and in sharing multiple in cancer both initial based across results in months. models, anticipate
our We ADC partners has Bielefeld. and through to magic the University – with now also and with integrated also RADR leverage been collaboration through based cryptophycin ADC module our development multiple our opportunities also plan through that to into with fully launch of Lantern,
believe significant larger for a ADCs opportunities with We license also and modality with partnership very companies. pharma treatment to are promising
to Our potential the AI enhancing simultaneously development the ADCs. effective immense while process de-risk and strategy ADC holds guided targeted of creation
the Given global XXXX. years billion billion, of by course the $X next to reach over the valued currently rapidly market ADC it’s $XX projected growing in but several
in and versioning We’re this our eager to space. expand important footprint
worldwide of and synthesize, be Under leadership linked Sewald property from ADCs generally includes IP testing option the license optimize will initial from intellectual the directed this – efforts. of provide IP our our exclusive Lantern team from University has joint of the terms University, the cryptophycin will generally to Bielefeld Dr. and this under this at Bielefeld collaboration collaboration, and the
of pace we year we’re sharing fourth anticipate end. than billion focused and – results now XX points oncology to to points We more XX points, during the on data quarter. data are surpass Leveraging now up the work billion probably data this XX by
yielding response and Our selection. RADR automated biological identification, prediction both be scale response tumors large an for platform patient excels can drug and network analysis, that analysis and leveraged target correlations
it’s But of just quality not about the data.
in to evolve platform terms its Our also of continues capabilities. RADR
massive to can quarter, groundbreaking launched blood-brain thousands targeting of do where challenging of crucial treatments, processing the often accurately importantly, models and by day some barrier amounts blood-brain this money permeability for in We permeability enable early capability barriers time therapies, blood-brain optimize permeability any The assess of and are is that pretty design targeting of potential of us that the neurological compound. a and compound. the tens and barrier stage development. disorders, can compounds We second for the During now. that and we availability of delivery involved predicting understanding more save predictive in developing unique
data, usage the now immune mutation power immune inhibitors. about more not predictive vast and more quarter, platform’s data, for analyze checkpoint predict modules, inhibitors. data, immune of of can these identify may of patients response the harnesses or investments pharmas this may checkpoint data now this to downstream to also now into our includes importantly RADR the and proteomic to to and data these patient larger allows extends long-term respond later potential machine power for We’ll for this combination manage antigen the their combinations module talk personalized inhibitors. to amounts And Furthermore, of but treatment both very that actually how value learning but and AI also checkpoint us strategies, data. And RNA
discussed, minimizing already potency we this damage I our systems. ADC designing the strides way for made think to templates significant the payloads for module, are potential to and while using therapeutic also created we generation has and ADCs as revolutionize the better And healthy ADCs and tissue high next have
personalized – So in and RADR we secure therapy size drug to that in the will Lantern’s cancer And leading at position functionality. secure forefront believe discovery capabilities its also continue of edge and development. continues to advance but both AI-based this scope,
shaping and therapies have journey started Lantern, precise into increasing future being time to on same cancer, XXXX our cancer the potentially insights in is towards functionality fostering entering now patients and the improving pivotal where and of the year hopefully with of for shift more are an the we’re dedication meaningful our company, becoming our their AI a at into of exciting a and where So effective efforts setting lives collective us and our transformational therapies. touching platform, trajectory for patients
second One – advance enrollment sites primary where further the be our we’ve LP-XXX. the X up of for We’ve and initial focus we’re this today. the It’ll to of half advance the actively enrollment in also trial, will Phase opened year up to during be Harmonic. patients screening opened our
We launch for also expect LP-XXX coming Phase X QX to months, likely of our XXXX. in in the trial most
as in drug pursuit These trials in mark milestones into pursuit milestones discovery significant our of mark significant the the the – of powered advancing AI clinic.
Additionally, and patients we Starlight X/X manner, our commitment cancers CNS and as plan think Phase this known STARXXX, our LP-XXX, on trials needs towards addressing we unmet through and clinical Therapeutics. Starlight. progressing for in is upside our massive under we a investors brain this think focused and to And underscores
portfolio a discovery, platform These will will partners. So ADC immune data research and progress for points we establish AI with standard over in the and our development. companies XX side, for drug reach based and milestones inhibitors our billion with data-driven RADR but set that believe new checkpoint modules collaborations key also further for will new
to opportunities licensing future and to to intend our franchise. our patients approach for partnership biopharma the and explore showcase how investors drive the AI and therapies can to also for accelerate of generate results actively companies path our We driven with
we’ll efforts, R&D our forward further for drive ambitiously fiscal we uphold discipline to value our management create to continue shareholders. While
same and with position managing we validating we developing cash we’re but which are we and As companies. larger the how managing the our assets pace insights, at these out, pointed for have time accelerating partnering at also we’re
diverse findings continue advance we we’ll over at several the coming portfolio, As be to months. data presenting notable very and new our scientific important conferences
of of coming and inhibit the August adult especially Cancer findings the data tumor one will pediatric San and we LP-XXX’s to CNS at to Oncology, to in growth, Neuro-Oncology on American new share Conference ATRT. XX Society in have where We related cell and CNS Society up the ability Francisco, related Clinical
Bhatia identifying whole we’ll Officer, will in in on about also And at Chief and tumor International where Kishor our approach for AI presenting on modules selectivity Conference new driven targets showcasing Germany tumor our We XX, August drug with details Conjugates be Scientific of Darmstadt, will fact, selectivity. Directed Drug be there. our improved antibody to be the innovative ADC Therapy kind
We’ll Texas non-Hodgkin’s September the genetic its lymphoma. ability Hematologic also LP-XXX Oncology’s where in related in X, be to of Meeting be on new research to target Society Annual sharing presenting at deficiencies Houston, we’ll and
clinical we of which coming scientific for have be and a Pharma. over that’ll will So months, the presented more for Lantern data exciting lot improved set groundwork the opportunities even
team, unwavering support In to want their to I and closing, our partners, stakeholders gratitude helping the my really investors and also to for dedication express our transform collaborators, our oncology our process. and us development
AI at I a solving precision era golden that to world the think proprietary that I oncology with in at We we’re this think problems a new brighter of forefront solutions way said future timelines of in medicine of. towards due lighting have significantly age of a and allow and unique together the drug development unheard real us AI. reduced places Lantern costs been to develop these oncology therapies as
scientific for scientific know endeavors. we miss Dr. clarifications, on but like for to up will to With I both wish our our take also has call moment in I’d that, now like the efforts, or his new Sturtevant, five his focused and I’d questions press colleague last Lantern, been thank any and a to team earnings personally Drew his to for the the well him but to communication upbeat dedication involvement open community, in who helping our calls.
from questions let’s take audience. again, So our
